Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BAY2287411 |
Synonyms | |
Therapy Description |
BAY2287411 is a radioimmunoconjugate consisting of the radionuclide thorium-227 linked to the mesothelin (MSLN) targeting antibody BAY 86-1903 (anetumab), which induces DNA damage and cell cycle arrest, potentially resulting in increased apoptosis, reduced cell viability, and inhibition of tumor growth (PMID: 31064781). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BAY2287411 | BAY-2287411|BAY 2287411|Th 227 Anetumab | MSLN Antibody 12 | BAY2287411 is a radioimmunoconjugate consisting of the radionuclide thorium-227 linked to the mesothelin (MSLN) targeting antibody BAY 86-1903 (anetumab), which induces DNA damage and cell cycle arrest, potentially resulting in increased apoptosis, reduced cell viability, and inhibition of tumor growth (PMID: 31064781). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03507452 | Phase I | BAY2287411 | First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin | Completed | USA | SWE | NLD | GBR | FIN | 0 |